Randomized clinical trial on the effects of adenosine 5'-triphosphate infusions on quality of life, functional status, and fatigue in preterminal cancer patients

Journal of Pain and Symptom Management

Volumn 40, Issue 4, 2010, Pages 520-530

  Beijer, Sandra ^a   Hupperets, Pierre S ^a   Van Den Borne, Ben E E M ^b   Wijckmans, Nicole E G ^a   Spreeuwenberg, Cor ^a   Van Den Brandt, Piet A ^a   Dagnelie, Pieter C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

Author keywords

ATP; cancer; functional status; quality of life

Indexed keywords

ADENOSINE TRIPHOSPHATE;

AGED; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; ELBOW FLEXION; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED TUMOR; MUSCLE STRENGTH; NEOPLASM; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TERMINAL CARE;

ACTIVITIES OF DAILY LIVING; ADENOSINE TRIPHOSPHATE; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; LACTOSE; METHACRYLATES; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 77957778148     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2010.01.023     Document Type: Article

References (36)

1. World Health Organization WHO mortality database Available from http://www.who.int/healthinfo/morttables Accessed 2005
2. J.H. Von Roenn, and J.A. Paice Control of common, non-pain cancer symptoms Semin Oncol 32 2 2005 200 210
3. S.C. Teunissen, W. Wesker, and C. Kruitwagen Symptom prevalence in patients with incurable cancer: a systematic review J Pain Symptom Manage 34 1 2007 94 104
4. A.S. Stromgren, M. Groenvold, L. Pedersen, A.K. Olsen, and P. Sjogren Symptomatology of cancer patients in palliative care: content validation of self-assessment questionnaires against medical records Eur J Cancer 38 6 2002 788 794
5. R.S. Lo, J. Woo, and K.C. Zhoc Quality of life of palliative care patients in the last two weeks of life J Pain Symptom Manage 24 4 2002 388 397
6. M. Groenvold, M.A. Petersen, and N.K. Aaronson The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care Eur J Cancer 42 1 2006 55 64
7. R. Kurzrock The role of cytokines in cancer-related fatigue Cancer 92 6 Suppl 2001 1684 1688
8. V.E. Baracos Cancer-associated cachexia and underlying biological mechanisms Annu Rev Nutr 26 2006 435 461
9. G. Mantovani, A. Maccio, and L. Mura Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites J Mol Med 78 10 2000 554 561
10. O. Minton, P. Stone, A. Richardson, M. Sharpe, and M. Hotopf Drug therapy for the management of cancer related fatigue Cochrane Database Syst Rev 1 2008 CD006704
11. L. Radbruch, F. Strasser, and F. Elsner Fatigue in palliative care patients - an EAPC approach Palliat Med 22 1 2008 13 32
12. H.J. Agteresch, P.C. Dagnelie, J.W. van den Berg, and J.H. Wilson Adenosine triphosphate: established and potential clinical applications Drugs 58 2 1999 211 232
13. E.L. Swennen, A. Bast, and P.C. Dagnelie Immunoregulatory effects of adenosine 5'-triphosphate on cytokine release from stimulated whole blood Eur J Immunol 35 3 2005 852 858
14. E.L. Swennen, A. Bast, and P.C. Dagnelie Purinergic receptors involved in the immunomodulatory effects of ATP in human blood Biochem Biophys Res Commun 348 3 2006 1194 1199
15. P. Collins, C. Bing, P. McCulloch, and G. Williams Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans Br J Cancer 86 3 2002 372 375
16. P.L.R. Andrews, G.R. Morrow, and J.T. Hickok Mechanisms and models of fatigue associated with cancer and its treatment: evidence of pre-clinical and clinical studies J. Armes, M. Krishnasamy, I. Higginson, Fatigue in cancer 2004 Oxford University Press Oxford, UK 51 87
17. C.G. da Silva, R. Jarzyna, A. Specht, and E. Kaczmarek Extracellular nucleotides and adenosine independently activate AMP-activated protein kinase in endothelial cells: involvement of P2 receptors and adenosine transporters Circ Res 98 5 2006 e39 e47
18. M. Daval, F. Foufelle, and P. Ferre Functions of AMP-activated protein kinase in adipose tissue J Physiol 574 Pt 1 2006 55 62
19. H.J. Agteresch, P.C. Dagnelie, A. van der Gaast, T. Stijnen, and J.H. Wilson Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 92 4 2000 321 328
20. H.J. Agteresch, S.A. Burgers, A. van der Gaast, J.H. Wilson, and P.C. Dagnelie Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients Anticancer Drugs 14 8 2003 639 644
21. S. Beijer, E. van Rossum, and P.S. Hupperets Application of adenosine 5'-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial BMC Public Health 7 2007 4
22. S. Beijer, P.S. Hupperets, and B.E. van den Borne Effect of adenosine 5'-triphosphate infusions on the nutritional status and survival of preterminal cancer patients Anticancer Drugs 20 7 2009 625 633
23. C.M. Haskell, E. Mendoza, K.M. Pisters, F.V. Fossella, and R.A. Figlin Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer Invest New Drugs 16 1 1998 81 85
24. N.K. Aaronson, A.M. Cull, S. Kaasa, and M.A.G. Sprangers The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology: an update B. Spilker, Quality of life and pharmacoeconomics in clinical trials 2nd ed 1996 Lippincott-Raven Philadelphia, PA 179 189
25. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 5 1993 365 376
26. M. Kyriaki, T. Eleni, and P. Efi The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample Int J Cancer 94 1 2001 135 139
27. S. Kaasa, K. Bjordal, and N. Aaronson The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy Eur J Cancer 31A 13-14 1995 2260 2263
28. T.P. Suurmeijer, D.M. Doeglas, and T. Moum The Groningen Activity Restriction Scale for measuring disability: its utility in international comparisons Am J Public Health 84 8 1994 1270 1273
29. J.H. Vercoulen, C.M. Swanink, and J.F. Fennis Dimensional assessment of chronic fatigue syndrome J Psychosom Res 38 5 1994 383 392
30. E.M. Smets, B. Garssen, B. Bonke, and J.C. De Haes The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue J Psychosom Res 39 3 1995 315 325
31. M. Alberts, E.M. Smets, J.H. Vercoulen, B. Garssen, and G. Bleijenberg ["Abbreviated fatigue questionnaire": a practical tool in the classification of fatigue] Ned Tijdschr Geneeskd 141 31 1997 1526 1530 [in Dutch]
32. M.A. Sprangers, and C.E. Schwartz Integrating response shift into health-related quality of life research: a theoretical model Soc Sci Med 48 11 1999 1507 1515
33. I.S. Breetvelt, and F.S. Van Dam Underreporting by cancer patients: the case of response-shift Soc Sci Med 32 9 1991 981 987
34. M.A. Andrykowski, S.L. Curran, and J.L. Studts Psychosocial adjustment and quality of life in women with breast cancer and benign breast problems: a controlled comparison J Clin Epidemiol 49 8 1996 827 834
35. A. van't Spijker, R.W. Trijsburg, and H.J. Duivenvoorden Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980 Psychosom Med 59 3 1997 280 293
36. M.R. Visser, E.M. Smets, M.A. Sprangers, and H.J. de Haes How response shift may affect the measurement of change in fatigue J Pain Symptom Manage 20 1 2000 12 18